Bad news has been factored into this stock before earnings. Approaching 52 week low. Buy light lite and penny beat on earnings was better then expected. International drag has already been factored into this stock and can't believe the brutal drop today on something that was a forgone conclusion here. Strong buy at these levels.
Sentiment: Strong Buy
St. Jude's (STJ) new CardioMEMS heart failure monitoring device makes it the most attractive stock among the top three heart-device companies, says Needham, which initiates coverage of STJ with a strong buy. With hospitals under pressure to reduce heart failure readmissions plus a new Medicare add-on payment, CardioMEMS is poised to drive sustainable 8%-10% EPS growth for STJ, Needham says. The firm also starts Medtronic (MDT) at a buy and Boston Scientific (BSX) at hold. It says growth for the sector is shifting to new products and emerging markets.
St. Jude Medical could surprise and easily buy out this small stem cell therapeutics company very cheaply before it becomes well known. This little company clearly owns the most powerful clinical trial results in history and has a tiny market cap of $35 million.
When the power of stem cell therapy is soon realized due to trial results below, it is understandable that stem cell therapy is about to change medicine forever.
This is why this $2.00 Stem Cell Stock Will Become $100.
Cesca therapeutics (KOOL) recently announced record shattering clinical trial results from their 17 patient CLI trial:
Before treatment, 100% of patients required amputation
12 months after treatment, 82.4% of patients had no amputation
Pain level before treatment on a scale of 0 to 10 was severe at 7.8
Pain level 12 months after treatment was almost non-existent at 0.2
6-minute walking distance before treatment was 14.5 meters
6-minute walking distance 12 months after treatment was 157meters
Before treatment, 11 patients had gangrene with or without ulceration
12 months after treatment 0 patients had gangrene or ulceration
NEW BLOOD VESSELS WERE REGENERATED AFTER TREATMENT.
THERE WERE NO ADVERSE SIDE EFFECTS.
They have similar results for AMI and orthopedic union and have already filed Pre-IDE with FDA for CLI.
St Jude Medical or estute Investors can buy Cesca at $20.00 in 12 months when more trial results are announced or they can buy Cesca today at under $2.00.
Sentiment: Strong Buy
Made over $70k this month on STJ trading thanks to underground stock alerts (google them) I get my stock alerts from them. They put out a report on the S&P 500 a few months ago and were SPOT on. Good luck all longs!
I actually didn't think I'd get out from underwater with STJ, but today was a real blessing. Made a profit even.